Rapamycin (Sirolimus)

off-label Rx · co-headlineFDA-approved · off-label

mTORC1 inhibition; autophagy; geroscience

Overview

Rapamycin (sirolimus) — mTOR inhibitor and the most-studied off-label geroscience drug. Intermittent weekly dosing targets mTORC1 for healthspan/immune modulation while limiting the immunosuppression of daily transplant dosing. Requires real clinician oversight.

How it works

mTORC1 inhibition
Autophagy induction
Cellular senescence / immune modulation

Dosing

Longevity: ~5–6 mg once weekly (protocols vary 3–8 mg/wk).

Oral6 mg standard· once weekly (pulsed)

Cycling

Weekly pulse; periodic breaks per clinician

Side effects

Common: Aphthous mouth ulcers
Transient lipid/glucose elevation
GI upset
Warnings: Immunosuppression / infection risk
Impaired wound healing
Hold around live vaccines and surgery

Verified citations

3 · PubMed-checked

Rapamycin fed late in life extends lifespan in genetically heterogeneous mice.preclinicalPMID 19587680 ↗
Targeting ageing with rapamycin and its derivatives in humans: a systematic review.clinicalPMID 38310895 ↗
Targeting the biology of aging with mTOR inhibitors.reviewPMID 37142830 ↗

Reconstitution

Not applicable — this compound is oral. No vial reconstitution needed.

Used for

Healthspan / longevityleadEmerging

Legal / compounding

FDA-approved · off-label

FDA: Approved (transplant); longevity use off-label

Legal status is a hard gate: non-compoundable or delisted agents cannot be filled and are blocked from protocol export. Keep 503A status current.